News & Updates

Show Multimedia Only

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026 by

The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026

Prophylactic vitamin K refusal may have adverse consequences for newborns

25 Jul 2026

The number of infants not receiving intramuscular vitamin K to prevent bleeding episodes is increasing, and this translates to an increased risk of bleeding episodes, including intracranial haemorrhages, according to a nationwide cohort study from Sweden.

Prophylactic vitamin K refusal may have adverse consequences for newborns

25 Jul 2026

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

24 Jul 2026

Treatment with carvedilol, compared with nadolol or propranolol, results in reduced rates of major decompensation events among patients with cirrhosis, a study has shown.

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

24 Jul 2026

Survodutide promotes weight loss in adults with obesity

24 Jul 2026

In patients with obesity but without diabetes, treatment with survodutide results in substantial reductions in body weight compared with placebo, according to the phase III SYNCHRONIZE-1 trial.

Survodutide promotes weight loss in adults with obesity

24 Jul 2026

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026 by

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026

Patients with liver cirrhosis may sleep better with lemborexant

23 Jul 2026 by

Treatment with lemborexant helps manage sleep disturbances in patients with liver cirrhosis, as shown in the crossover RESTORE trial.

Patients with liver cirrhosis may sleep better with lemborexant

23 Jul 2026

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in an increased risk for ischaemic optic neuropathy (ION) at 18 months when compared with the use of sodium‒glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is), reports a study.

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

Obinutuzumab outperforms tacrolimus in primary membranous nephropathy

23 Jul 2026

Among patients with primary membranous nephropathy, those treated with obinutuzumab are more likely to achieve complete remission than those treated with tacrolimus, according to the phase III MAJESTY trial.

Obinutuzumab outperforms tacrolimus in primary membranous nephropathy

23 Jul 2026

Abbreviated DAPT found safe in high-risk patients undergoing PCI

22 Jul 2026

In patients at high risk of bleeding who are undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) durations, especially 3-month regimens, reduces bleeding events without increasing the risk of fatal or nonfatal ischaemic cardiovascular or cerebrovascular events when compared with standard DAPT durations, according to a meta-analysis.

Abbreviated DAPT found safe in high-risk patients undergoing PCI

22 Jul 2026

Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification

22 Jul 2026 by

Treatment with the thyroid hormone beta agonist resmetirom significantly improves qFibrosis continuous values (qFC), categorical stages (qFS), and individual collagen features associated with fibrosis progression at week 52 compared with placebo in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), as shown in the phase III MAESTRO-NASH trial.

Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification

22 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

GLP-1RA exposure lowers mortality in patients with dementia

GLP-1RA exposure lowers mortality in patients with dementia

Prophylactic vitamin K refusal may have adverse consequences for newborns

Prophylactic vitamin K refusal may have adverse consequences for newborns

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

Carvedilol outdoes nadolol, propranolol in preventing decompensation events in cirrhosis

Survodutide promotes weight loss in adults with obesity

Survodutide promotes weight loss in adults with obesity

Venglustat superior to ERT in Gaucher disease type 3

Venglustat superior to ERT in Gaucher disease type 3

Patients with liver cirrhosis may sleep better with lemborexant

Patients with liver cirrhosis may sleep better with lemborexant

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

Obinutuzumab outperforms tacrolimus in primary membranous nephropathy

Obinutuzumab outperforms tacrolimus in primary membranous nephropathy

Abbreviated DAPT found safe in high-risk patients undergoing PCI

Abbreviated DAPT found safe in high-risk patients undergoing PCI

Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification

Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification